Anavex Life Sciences Corp
Suletud
SektorTervishoid
3.34 1.83
Ülevaade
Aktsiahinna muutus
24h
Min
3.2800000000000002
Max
3.39
Sissetulek | 4.1M -5.7M |
|---|---|
Aktsiakasum | -0.06 |
Töötajad | 34 |
EBITDA | -821K -6.5M |
Järgmine tulemuste avaldamine | 11. aug 2026 |
|---|
Turukapital | 42M 273M |
|---|---|
Eelmine avamishind | 1.51 |
Eelmine sulgemishind | 3.34 |
Uudiste sentiment
By Acuity
86%
14%
321 / 340 Pingereas Healthcare
Anavex Life Sciences Corp Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Anavex Life Sciences Corp Prognoos
Sentiment
By Acuity
321 / 340 Pingereas Tervishoid
Uudiste sentiment
Väga tugevad languse märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Üle keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Anavex Life Sciences Corp
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
